| Date | Time | Source | |
| 09/19/2024 | 4:01PM | PRNUS | Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit
Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit PR Newswire SAN DIEGO, Sept. 19, 2024 SAN DIEGO, Sept. 19, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry... More...>> |
| 09/12/2024 | 4:05PM | PRNUS | Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia
Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia PR Newswire SAN DIEGO, Sept. 12, 2024 Second Phase 2 Study for Luvadaxistat Fails to Meet Primary Endpoint as Potential Treatment for Cognitive Impairment Associated with... More...>> |
| 09/10/2024 | 4:01PM | PRNUS | Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare Conference
Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare Conference PR Newswire SAN DIEGO, Sept. 10, 2024 SAN DIEGO, Sept. 10, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the 2024 Cantor Global Healthcare Conference in New York at 3:05 p.m. Eastern Time on Tuesday... More...>> |
| 08/28/2024 | 4:05PM | PRNUS | Neurocrine Biosciences to Participate at Investor Conferences in September
Neurocrine Biosciences to Participate at Investor Conferences in September PR Newswire SAN DIEGO, Aug. 28, 2024 Morgan Stanley 22nd Annual Global Healthcare Conference on September 4 in New York 2024 Wells Fargo Healthcare Conference on September 5 in Boston SAN DIEGO, Aug. 28, 2024 /PRNewswire/ -- Neurocrine Biosciences... More...>> |
| 08/28/2024 | 7:00AM | PRNUS | Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia PR Newswire SAN DIEGO, Aug. 28, 2024 The Once-Daily 20 mg Dose Met the Primary Endpoint, Demonstrating a Statistically Significant 7.5-Point Improvement (p=0.011, 0.61 Effect Size) in the PANSS Total Score Compared to Placebo... More...>> |
| 08/07/2024 | 4:01PM | PRNUS | Neurocrine Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference
Neurocrine Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference PR Newswire SAN DIEGO, Aug. 7, 2024 SAN DIEGO, Aug. 7, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Canaccord Genuity 44th Annual Growth Conference in Boston at 3:30 p.m. Eastern Time on Wednesday... More...>> |
| 08/01/2024 | 7:00AM | PRNUS | Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance
Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance PR Newswire SAN DIEGO, Aug. 1, 2024 INGREZZA® (valbenazine) Second Quarter Net Product Sales of $580 Million Representing 32% Year-Over-Year Growth INGREZZA® (valbenazine) 2024 Net Product Sales Guidance Raised... More...>> |
| 07/18/2024 | 8:30AM | PRNUS | Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing PR Newswire SAN DIEGO, July 18, 2024 SAN DIEGO, July 18, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the launch of a new sprinkle... More...>> |
| 07/11/2024 | 4:01PM | PRNUS | Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results PR Newswire SAN DIEGO, July 11, 2024 Conference Call and Webcast Scheduled for Thursday, August 1 SAN DIEGO, July 11, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled... More...>> |
| 07/01/2024 | 7:30AM | PRNUS | Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH
Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH PR Newswire SAN DIEGO, July 1, 2024 PDUFA Target Action Dates in Late December 2024Highly Selective CRF1 Antagonist is the Potential First New Treatment for CAH in... More...>> |
| 06/03/2024 | 8:01AM | PRNUS | Neurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024
Neurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024 PR Newswire SAN DIEGO, June 3, 2024 SAN DIEGO, June 3, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Diurnal Ltd... More...>> |
| 06/03/2024 | 7:35AM | PRNUS | Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine PR Newswire SAN DIEGO, June 3, 2024 - CAHtalyst™ Pediatric Study Met Primary and Key Secondary Endpoints, with Crinecerfont... More...>> |
| 06/03/2024 | 7:30AM | PRNUS | Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine PR Newswire SAN DIEGO, June 3, 2024 - CAHtalyst™ Adult Phase 3 Study Met Primary and Important Key Secondary Endpoints... More...>> |
| 05/29/2024 | 4:01PM | PRNUS | Neurocrine Biosciences to Participate at Investor Conferences in June
Neurocrine Biosciences to Participate at Investor Conferences in June PR Newswire SAN DIEGO, May 29, 2024 Jefferies Global Healthcare Conference on June 5 in New York Goldman Sachs 45th Annual Global Healthcare Conference on June 13 in Miami SAN DIEGO, May 29, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq:... More...>> |
| 05/28/2024 | 4:14PM | PRNUS | Neurocrine Biosciences Announces CEO Succession Plan
Neurocrine Biosciences Announces CEO Succession Plan PR Newswire SAN DIEGO, May 28, 2024 Board of Directors appoints Kyle Gano, Ph.D., Chief Business Development and Strategy Officer, as CEO-elect, effective October 11, 2024 Kevin Gorman, Ph.D., to continue to serve on the Neurocrine Board of Directors SAN DIEGO, May... More...>> |
| 05/28/2024 | 8:30AM | PRNUS | Neurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024
Neurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024 PR Newswire SAN DIEGO, May 28, 2024 New CAHtalyst™ Pediatric and CAHtalyst™ Adult Phase 3 Clinical Study Data... More...>> |
| 05/21/2024 | 4:05PM | PRNUS | Neurocrine Biosciences Announces Publication of Phase 3 KINECT®-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZZA® (valbenazine) Capsules
Neurocrine Biosciences Announces Publication of Phase 3 KINECT®-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZZA® (valbenazine) Capsules PR Newswire SAN DIEGO, May 21, 2024 SAN DIEGO, May 21, 2024 /PRNewswire/ -- Neurocrine Biosciences... More...>> |
| 05/14/2024 | 8:30AM | PRNUS | Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024
Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024 PR Newswire SAN DIEGO, May 14, 2024 - CAHtalyst™ Phase 3 Baseline Characteristics Highlight Limitations of Current CAH Treatment Paradigm... More...>> |
| 05/09/2024 | 9:45AM | PRNUS | Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024
Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024 PR Newswire SAN DIEGO, May 9, 2024 CAHtalyst™ Study Baseline Characteristics Highlight the Need for New Treatment Options to Reduce Adrenal Androgens and Supraphysiologic... More...>> |
| 05/09/2024 | 8:30AM | PRNUS | Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults PR Newswire SAN DIEGO, May 9, 2024 SAN DIEGO, May 9, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 1 first-in-human clinical study to evaluate... More...>> |